Semaglutide for Kidney Disease: What the Evidence Shows
What human and animal studies show about Semaglutide for kidney disease, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 2
- with an outcome for kidney disease, in our evidence file (PubMed search, 2 Oct 2026)
- Animal studies
- None found
- with an outcome for kidney disease, in our evidence file (PubMed search, 2 Oct 2026)
- Studies we summarised
- 2
- with an outcome for kidney disease
Evidence for kidney disease
Each row is an outcome related to kidney disease from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Albuminuria | After 24 weeks, urinary albumin-to-creatinine ratio was reduced by 52.1% with semaglutide vs placebo. | Human RCTn = 101 | Nature medicine 2025, PMID 39455729 |
| Major kidney disease events | The risk of the primary kidney composite was 24% lower with semaglutide (331 vs 410 first events; hazard ratio 0.76). | Human RCTn = 3533 | The New England journal of medicine 2024, PMID 38785209 |
| Major cardiovascular events | The risk of major cardiovascular events was 18% lower (hazard ratio 0.82). | Human RCTn = 3533 | The New England journal of medicine 2024, PMID 38785209 |
Semaglutide and kidney disease are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our evidence scale.
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for kidney disease
No other peptide in our index has a kidney disease page yet.
Common questions
Does Semaglutide help with kidney disease?
The strongest study we summarise for kidney disease is human rct evidence, across 2 studies with an outcome for kidney disease. A trial result is not an approval; see the legal status.
Is Semaglutide approved for kidney disease?
Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.
More on Semaglutide
Sources
- 1Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.Nature medicine · 2025PMID 39455729Accessed 2 Oct 2026
- 2Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.The New England journal of medicine · 2024PMID 38785209Accessed 2 Oct 2026
Found an error? Report a correction.